Details

Autor(en) / Beteiligte

• Pinto, Dora
• Park, Young-Jun
• Beltramello, Martina
• Walls, Alexandra C.
• Tortorici, M. Alejandra
• Bianchi, Siro
• Jaconi, Stefano
• Culap, Katja
• Zatta, Fabrizia
• De Marco, Anna
• Peter, Alessia
• Guarino, Barbara
• Spreafico, Roberto
• Cameroni, Elisabetta
• Case, James Brett
• Chen, Rita E.
• Havenar-Daughton, Colin
• Snell, Gyorgy
• Telenti, Amalio
• Virgin, Herbert W.
• Lanzavecchia, Antonio
• Diamond, Michael S.
• Fink, Katja
• Veesler, David
• Corti, Davide

Titel

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Ist Teil von

• Nature (London), 2020-07, Vol.583 (7815), p.290-295

Ort / Verlag

London: Nature Publishing Group UK

Erscheinungsjahr

2020

Quelle

MEDLINE

Beschreibungen/Notizen

• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly emerged coronavirus that is responsible for the current pandemic of coronavirus disease 2019 (COVID-19), which has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 2020 1 , 2 . Vaccine and therapeutic discovery efforts are paramount to curb the pandemic spread of this zoonotic virus. The SARS-CoV-2 spike (S) glycoprotein promotes entry into host cells and is the main target of neutralizing antibodies. Here we describe several monoclonal antibodies that target the S glycoprotein of SARS-CoV-2, which we identified from memory B cells of an individual who was infected with severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003. One antibody (named S309) potently neutralizes SARS-CoV-2 and SARS-CoV pseudoviruses as well as authentic SARS-CoV-2, by engaging the receptor-binding domain of the S glycoprotein. Using cryo-electron microscopy and binding assays, we show that S309 recognizes an epitope containing a glycan that is conserved within the Sarbecovirus subgenus, without competing with receptor attachment. Antibody cocktails that include S309 in combination with other antibodies that we identified further enhanced SARS-CoV-2 neutralization, and may limit the emergence of neutralization-escape mutants. These results pave the way for using S309 and antibody cocktails containing S309 for prophylaxis in individuals at a high risk of exposure or as a post-exposure therapy to limit or treat severe disease. The monoclonal antibody S309, identified from memory B cells of an individual infected with SARS-CoV in 2003, or antibody cocktails that contain this antibody potently neutralize SARS-CoV-2.